Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137121 · ClinicalTrials.gov registry record · Phase 2
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
A Phase 2 study of Advanced Cancer, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT03137121: Completed Phase 2 study of Advanced Cancer, sponsored by University of Alabama at Birmingham.
NCT03137121 is a Phase 2 study of Advanced Cancer that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03137121, a Phase 2 study of Advanced Cancer, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the use of olanzapine for the treatment of cancer patients with chronic nausea and/or vomiting unrelated to chemotherapy or radiation in a randomized placebo-controlled pilot trial.
Primary Outcome
Daily nausea scores (the primary objective) on day 1 to 7 of treatment for each patient from the Olanzapine and Placebo group will be measured using the Visual Analogue Scale rankings from 0-10 where 0 is no nausea and 10 is the maximum nausea experienced by a patient. A Visual Analogue Scale is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that can't be directly measured. Patients will be asked to r
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Olanzapine
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
Indiana
- Indiana University - Indianapolis
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
Wisconsin
- Hospital Sisters Health System (HSHS) St. Vincent Hospital - Green Bay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2020-09-15 |
| Phase | Phase 2 |
What the finished NCT03137121 record still lists
NCT03137121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03137121 lists 5 locations in 5 states (Alabama, Indiana, Minnesota).
Frequently Asked Questions
What is clinical trial NCT03137121 about?
NCT03137121 is a clinical study titled "Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients". The purpose of this study is to evaluate the use of olanzapine for the treatment of cancer patients with chronic nausea and/or vomiting unrelated to chemotherapy or radiation in a randomized placebo-controlled pilot trial.
What is the current status of trial NCT03137121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-07-12. Estimated completion is 2020-09-15.
What conditions does trial NCT03137121 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT03137121?
The interventions under investigation include: Placebo (OTHER), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT03137121?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03137121 being conducted?
This trial has 5 study locations across Alabama, Indiana, Minnesota, Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03137121's enrollment target sits among peer trials
30 97th of 122 higher than 20 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI